1. Home
  2. > Healthcare
  3. > Diagnostics Market Trends
Liquid Biopsy for Cancer Diagnostics – Competitive Landscape and Pipeline Analysis, 2022

Liquid Biopsy for Cancer Diagnostics – Competitive Landscape and Pipeline Analysis, 2022

  • July 2022
  • 60 pages
  • ID: 6222504
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Liquid Biopsy for Cancer Diagnostics – Competitive Landscape and Pipeline Analysis, 2022,” report provides an understanding of the current competition, pipeline products, and changing market dynamics of the Liquid Biopsy for Cancer Diagnostics market in the 7 major pharmaceutical markets. The report also gives a brief competitive analysis of both the current and emerging products, to help understand the competition in the market.

Liquid Biopsy for Cancer Diagnostics Understanding

Liquid Biopsy: Overview
Liquid biopsy is a revolutionary technique that consists of the detection and isolation of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes, as a source of genomic and proteomic information in patients with cancer. The major advantages of liquid biopsy in cancer diagnosis is that the technique is minimally-invasive, painless, does not have risk of complications, and gives faster results as compared to tumor biopsies. Some disadvantages and limitations of liquid biopsy include its lower accuracy and sensitivity as compared to tumor biopsies, and a lack of standardized protocols for isolation of components from the blood for mutation analysis.
Why use Liquid Biopsy instead of Tissue Biopsy?
• Minimal invasiveness
• No pain
• No risk of complications
• More compatibility with Longitudinal monitoring

Key Players
• Guardant Health
• Roche
• Neo Genomics
• Qiagen
• ArcherDX
• Bio-Techne
• Resolution Bioscience
• Personal Genome Diagnostics
• Laboratory for Advanced Medicine (LAM)
• Lucence Diagnostics
• Foundation Medicine Inc
• Biocept
• Sysmex Ionostics Inc
• Veridex LLC (Janssen Diagnostics)
• Biodesix
• Pathway Genomics
• Exact Sciences
• Angle Plc
• GRAIL Inc.
• NuProbe
• OncoCell MDx Inc
• Merck
• AmoyDx
Liquid Biopsy: Competitive Assessment
This segment of the report provides a brief competitive analysis of both the current and emerging products, to help understand the competition in the market. It has been segregated based on following parameters that define the scope of the report, such as:
• Analysis by Market Status
This report covers around approx. 20 major products segregated under marketed and emerging
• Marketed
• Emerging

• Analysis by Number of Industry Collaborations
Liquid Biopsy for cancer diagnostics report provides a complete analysis of all the major collaborations done by the key players for the development of the liquid biopsy test devices
• Snapshot of some key collaborations in the liquid Biopsy Market
• Guardant360 Cdx Assay (Guardant Health): 3 collaborations
• ArcherMET (ArcherDx): 2 collaborations
• Invisionfirst (Inviata): 1 collaboration
Further collaboration details are provided in the report…….
• Analysis by Turnaround Time
Products have been categorized under various turnaround time such as:
• Less than 2 days
• Less than 10 days
• Less than 5 days
• More than 10 days

• Analysis by Indication
Products have been categorized under different indications under the Cancer therapeutics such as:
• NSCLC
• Breast Cancer
• Prostate Cancer
• All Solid Tumors
• Liver Cancer
• Blood Cancer
• NTRK fusion Cancer
• Hepatocellular Carcinoma
• Head and Neck Cancer
• Many types of Cancer

• Analysis by Biomarker Type
Products have been classified according to the different biomarker types used in the detection of cancer through liquid Biopsy technique:
• CtDNA and cfDNA
• Exosomes in Urine
• Methylated ctDNA
• CTCs and ctDNA
• CTCs

• Major Players in Liquid Biopsy Market
There are approx. 20+ key companies which are developing the products for liquid biopsy products.
• Liquid Biopsy Cancer Test: GRAIL Inc.

Grail is developing multi-cancer early detection liquid biopsy test or blood test which can detect up to 50 types of cancer and is committed to is committed to develop a deep understanding of cancer biology. GRAIL is poised to detect cancer early by combining high-intensity sequencing of unprecedented breadth and depth with the techniques of modern data science. GRAIL is creating vast datasets to develop evidence supporting their products.
• Parsortix: Angle Plc

ANGLE’s Parsortix system has the potential to deliver profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer. Parsortix is different from many of its rivals as, rather than testing for fragments of dead cancer cells, it detects and captures circulating tumour cells (CTCs). CTCs provide the tell-tale signs of cancer and their capture can allow doctors to more accurately assess treatment options. This method is seen as more reliable because other tests have shown that fragments of dead cancer cells are present in around a quarter of people over 65 who do not have cancer. CTCs, on the other hand, give a complete picture because they can only be found in people with cancer.
• DNA methylation based liquid biopsy test: Exact Sciences
Exact’s DNA methylation based liquid biopsy test detects 80% of hepatocellular carcinoma (HCC) cases across all stages and 71% of early stage cases. It has shown better performance than the most commonly used marker for HCC, serum alpha-fetoprotein (AFP).
Liquid Biopsy for Cancer Diagnostics: Commercialization Activity
This segment of the report provides a detailed list of any commercial activity in the field of liquid biopsy products ranging from collaboration, mergers and acquisition, recent breakthrough among others.

Development Activities

• In November 2020, Grail has announced a commercial partnership with the UK’s National Health Service to make its early cancer liquid biopsy test available starting in 2021
• In June 22nd 2020, NuProbe and Weigao Group had announced a strategic collaboration to use NuProbe’s proprietary blocker displacement amplification (BDA) technology to develop a liquid biopsy next-generation sequencing panel for non-small cell lung cancer for the Chinese market.
Further commercial activities are provided in the report……..

Liquid Biopsy for Cancer Diagnostics: Regulatory Pathway

Liquid Biopsy: Regulatory Overview
The regulatory pathway for diagnostic is an alternative NDA process for approving a new diagnostic device. This segment provides an overview of how the regulatory bodies such as the FDA the diagnostics products, by classifying them into different classes which are Class I, II, or III according to the level of regulatory control that is necessary to reasonably assure safety and effectiveness.

Report Highlights
• The report covers Introduction of liquid biopsy for cancer diagnostics, including its applications, advantages, disadvantages and limitations, and technological considerations

• The report provides detailed product profiles for marketed products as well as pipeline products consisting of product description, regulatory milestones, research and development activities, along with product development activities
• The report gives a brief competitive analysis of both the current and emerging products, to help understand the competition in the market
• The report also reviews the driving and restraining factors for Liquid Biopsy for Cancer Diagnostics market in 7 MM
• The report helps in developing business strategies by understanding trends shaping and driving the global Liquid Biopsy for Cancer Diagnostics market

Liquid Biopsy Report Insights

• Liquid Biopsy in Cancer Diagnostic Overview

• Regulatory Overview
• Competitive Assessment
• Key Driver and Barriers
• Key strategic developments

Liquid Biopsy Report Assessment
• Marketed Product profiles
• Pipeline Product Profiles
• Industry Collaborations assessment
• Turnaround Time assessment
• Oncology Indication Assessment
• Biomarker Type Assessment

Key Questions
• How many companies are developing Liquid Biopsy Diagnostic devices?
• How many Liquid Biopsy Diagnostic devices are developed by each company?
• How many emerging liquid biopsy devices are there?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the liquid Biopsy in Cancer diagnostics market?
• What are the other key developments and happenings going on for the liquid Biopsy in Cancer diagnostic market domain and their status?
• What are the key designations that have been granted to the emerging diagnostic devices?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

DNA Test Kits Market Research Report by Sample Type, Application, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • $ 3949
  • January 2023
  • 251 pages

DNA Test Kits Market Research Report by Sample Type (Cheek Swab and Saliva), Application, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030 The ...

  • World
  • Genetic Testing
  • Industry analysis

ref:plp2022

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on